Shown verbatim: the complete text as captured from the official PDF posted by the Oklahoma Legislature, fetched 2026-07-23. Page and line markers are part of the official record; nothing is edited or removed. The official bill page.
1 STATE OF OKLAHOMA
1
2 2nd Session of the 60th Legislature (2026)
2
3 SENATE BILL 2024 By: Deevers
3
4
4
5
5
6 AS INTRODUCED
6
7 An Act relating to pharmaceutical products; defining
7 terms; requiring manufacturers of pharmaceutical
8 products to publish certain list of ingredients;
8 specifying certain inclusions; clarifying
9 applicability; requiring certain submission and
9 publication; providing administrative, civil, and
10 criminal penalties and remedies; granting certain
10 protection; requiring establishment of certain
11 reporting system; preempting certain rulemaking;
11 providing certain construction; providing for
12 codification; and providing an effective date.
12
13
13
14
14
15 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
15
16 SECTION 1. NEW LAW A new section of law to be codified
16
17 in the Oklahoma Statutes as Section 9002.1 of Title 63, unless there
17
18 is created a duplication in numbering, reads as follows:
18
19 As used in this act:
19
20 1. "Ingredient" includes:
20
21 a. all active and inactive components,
21
22 b. biological materials, such as mRNA, DNA from human or
22
23 animal sources, and viral vectors,
23
24
24
Req. No. 3505 Page 1
1 c. synthetic materials, including lipids, nanotechnology
1
2 components, and polymers, and
2
3 d. adjuvants, preservatives, stabilizers, and other
3
4 additives;
4
5 2. "Manufacturer" means any person or entity engaged in the
5
6 production, preparation, propagation, compounding, or processing of
6
7 pharmaceutical products, as defined in Section 353.1 of Title 59 of
7
8 the Oklahoma Statutes; and
8
9 3. "Pharmaceutical product" means any drug or device as defined
9
10 in Section 353.1 of Title 59 of the Oklahoma Statutes including
10
11 prescription drugs, over-the-counter medications, vaccines, and
11
12 products intended for research purposes.
12
13 SECTION 2. NEW LAW A new section of law to be codified
13
14 in the Oklahoma Statutes as Section 9002.2 of Title 63, unless there
14
15 is created a duplication in numbering, reads as follows:
15
16 A. Manufacturers of pharmaceutical products, including those
16
17 intended exclusively for research purposes, shall publish a complete
17
18 and detailed list of all ingredients for each product.
18
19 1. The list shall include:
19
20 a. the chemical and common names of all active, inactive,
20
21 biological, and synthetic ingredients,
21
22 b. the origin of any biological materials, specifying
22
23 whether they are derived from human, animal, or
23
24 synthetic sources,
24
Req. No. 3505 Page 2
1 c. the purpose of each ingredient, and
1
2 d. the quantity or concentration of each ingredient,
2
3 including trace elements and residuals.
3
4 2. For products containing mRNA or other gene-based technology,
4
5 the disclosure shall specify:
5
6 a. the sequence and source of any nucleic acids, and
6
7 b. the delivery mechanism, including synthetic carriers
7
8 such as lipid nanoparticles.
8
9 B. The ingredient information shall be:
9
10 1. Submitted to the State Board of Pharmacy;
10
11 2. Published publicly on a manufacturer-maintained website; and
11
12 3. Included in product labeling and marketing materials.
12
13 C. The responsibility to disclose all ingredients or components
13
14 of any pharmaceutical product, medical treatment, or mandate shall
14
15 remain unchanged regardless of whether a national emergency is
15
16 declared by the President of the United States or Congress. The
16
17 rights of individuals shall not be suspended, abridged, or infringed
17
18 during any declared emergency.
18
19 SECTION 3. NEW LAW A new section of law to be codified
19
20 in the Oklahoma Statutes as Section 9002.3 of Title 63, unless there
20
21 is created a duplication in numbering, reads as follows:
21
22 A. Noncompliance with the provisions of this act shall result
22
23 in the following penalties:
23
24
24
Req. No. 3505 Page 3
1 1. Fines up to Fifty Thousand Dollars ($50,000.00) per
1
2 violation, per product; and
2
3 2. Suspension or revocation of the right to distribute or sell
3
4 the noncompliant pharmaceutical product within this state until
4
5 compliance is achieved.
5
6 B. Enhanced penalties for repeated or willful violations shall
6
7 be assessed as follows:
7
8 1. Escalating fines:
8
9 a. on a second violation: fines up to One Hundred
9
10 Thousand Dollars ($100,000.00) per product, and
10
11 b. on a third or subsequent violation: fines up to Two
11
12 Hundred Fifty Thousand Dollars ($250,000.00) per
12
13 product;
13
14 2. Prohibition of operations: For continued noncompliance, the
14
15 manufacturer may be prohibited from distributing or selling any
15
16 pharmaceutical products in this state for up to one (1) year; and
16
17 3. Criminal liability: Repeated or intentional
17
18 misrepresentation or omission of ingredient information is a
18
19 misdemeanor crime punishable by up to one (1) year of imprisonment.
19
20 C. The following civil remedies shall be available:
20
21 1. Private right to civil action: Any individual or group
21
22 harmed by noncompliance with this act, including misrepresentation
22
23 or omission of ingredient information, may bring a civil lawsuit
23
24 against the manufacturer for damages including, but not limited to:
24
Req. No. 3505 Page 4
1 a. economic damages including, but not limited to,
1
2 medical expenses or financial losses,
2
3 b. noneconomic damages including, but not limited to,
3
4 pain and suffering or emotional distress, and
4
5 c. punitive damages, as appropriate under Oklahoma law;
5
6 and
6
7 2. Class action suit: Affected individuals may form a class to
7
8 seek collective remedy in cases of widespread harm resulting from
8
9 noncompliance.
9
10 D. The State of Oklahoma may seek injunctive relief to compel
10
11 compliance or halt the distribution and sale of noncompliant
11
12 pharmaceutical products.
12
13 E. Individuals who report violations of this act by
13
14 manufacturers shall be protected from retaliation under applicable
14
15 whistleblower statutes and may be entitled to a percentage of fines
15
16 collected as a result of their report.
16
17 F. The State Board of Pharmacy shall establish a reporting
17
18 system for individuals to file complaints regarding suspected
18
19 violations of this act, with such reports forwarded to the
19
20 Legislature for review and potential enforcement action.
20
21 SECTION 4. NEW LAW A new section of law to be codified
21
22 in the Oklahoma Statutes as Section 9002.4 of Title 63, unless there
22
23 is created a duplication in numbering, reads as follows:
23
24
24
Req. No. 3505 Page 5
1 The Legislature shall retain exclusive rulemaking authority to
1
2 implement and enforce the provisions of this act.
2
3 SECTION 5. NEW LAW A new section of law to be codified
3
4 in the Oklahoma Statutes as Section 9002.5 of Title 63, unless there
4
5 is created a duplication in numbering, reads as follows:
5
6 To the extent any laws conflict with this act, this act shall
6
7 govern.
7
8 SECTION 6. This act shall become effective January 1, 2027.
8
9
9
10 60-2-3505 BRC 1/15/2026 10:26:03 AM
10
11
11
12
12
13
13
14
14
15
15
16
16
17
17
18
18
19
19
20
20
21
21
22
22
23
23
24
24
Req. No. 3505 Page 6Every fact on this page links to its source, starting with the official bill record.